Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids

Sobral, Patricia Marial; Barros, Artur Emilio de Lima; Gomes, Ayla Maritcha Alves Silva; Bonfim, Cristine Vieira do

doi:10.5581/1516-8484.20120056

Cited by 13 publications

(7 citation statements)

References 25 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We showed that LT recipients had the higher prevalence of HPgV 29,30 Viral inactivation technology is not present in Japan as it is in other countries. 30 However, it is unknown whether…”

Section: Hpgv Infection In Lt Recipients and Clinical Factors And Outmentioning

confidence: 78%

“…Although this NAT technology is efficient in detecting HIV/HCV/HBV before blood transfusion, HPgV is not evaluated by it. In addition, there are viral inactivation technologies, such as solvent/detergent, methylene blue, amotosalen, and riboflavin in hemotherapy for decreasing blood‐borne pathogens . Viral inactivation technology is not present in Japan as it is in other countries .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of human pegivirus infection in liver transplantation recipients

Izumi

Sakata

Okuzaki

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Approximately 2% of healthy persons are infected with human pegivirus (HPgV). HPgV is transmitted via vertical, sexual, and blood‐borne routes. Recently, the association of HPgV infection with the risk of lymphoma was reported. Here, we examined the prevalence of chronic HPgV infection in liver transplantation (LT) recipients and patients with hepatectomy and the influence of HPgV infection after LT on clinical and perioperative factors. We enrolled 313 LT recipients and 187 patients with hepatectomy who received care at the Kyusyu University Hospital between May 1997 and September 2017. Of the 313 recipients and 187 patients enrolled in this study, 44 recipients (14.1%) and 2 patients (1.1%) had HPgV viremia, respectively. There was no significant association between HPgV infection and LT outcomes. Interestingly, one recipient was infected with HPgV during the peritransplant period, which was likely transmitted via blood transfusion because HPgV RNA was detected from the blood bag transfused to the recipient during LT. We reviewed the available literature on the prevalence HPgV infections in other organ‐transplanted patients and whether they impacted clinical outcomes. They also had the higher prevalence of HPgV infection, while it appears to be of low or no consequences. In addition, HPgV infection induced the upregulation of interferon‐stimulated gene (ISG) expression in peripheral blood mononuclear cells. LT recipients had higher HPgV viremia compared to patients with hepatectomy. Although HPgV infection was not associated with LT‐related outcomes, it induced ISG expression in recipients.

show abstract

“…We showed that LT recipients had the higher prevalence of HPgV 29,30 Viral inactivation technology is not present in Japan as it is in other countries. 30 However, it is unknown whether…”

Section: Hpgv Infection In Lt Recipients and Clinical Factors And Outmentioning

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Characterization of human pegivirus infection in liver transplantation recipients

Izumi

Sakata

Okuzaki

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…In addition to carbonyl groups, other types of covalent damage caused by formalin, UV, and gamma radiation can result in the formation of "neoantigens" and elicit adverse immune reactions when administered to patients, as was seen in penicillin allergies 30 and certain chemically treated blood products. 31 In contrast, the USP laser inactivates enveloped influenza virus through the disruption of weak, noncovalent hydrogen bonds and hydrophobic contacts in the virion, leading to the aggregation of capsid and tegument proteins. As a result, there is an overall reduced concern of side effects from vaccines prepared by the USP laser treatment method.…”

Section: Discussionmentioning

confidence: 99%

Chemical-free inactivated whole influenza virus vaccine prepared by ultrashort pulsed laser treatment

Tsen

Donthi

et al. 2014

J. Biomed. Opt

View full text Add to dashboard Cite

There is an urgent need for rapid methods to develop vaccines in response to emerging viral pathogens. Whole inactivated virus (WIV) vaccines represent an ideal strategy for this purpose; however, a universal method for producing safe and immunogenic inactivated vaccines is lacking. Conventional pathogen inactivation methods such as formalin, heat, ultraviolet light, and gamma rays cause structural alterations in vaccines that lead to reduced neutralizing antibody specificity, and in some cases, disastrous T helper type 2-mediated immune pathology. We have evaluated the potential of a visible ultrashort pulsed (USP) laser method to generate safe and immunogenic WIV vaccines without adjuvants. Specifically, we demonstrate that vaccination of mice with laser-inactivated H1N1 influenza virus at about a 10-fold lower dose than that required using conventional formalin-inactivated influenza vaccines results in protection against lethal H1N1 challenge in mice. The virus, inactivated by the USP laser irradiation, has been shown to retain its surface protein structure through hemagglutination assay. Unlike conventional inactivation methods, laser treatment did not generate carbonyl groups in protein, thereby reducing the risk of adverse vaccine-elicited T helper type 2 responses. Therefore, USP laser treatment is an attractive potential strategy to generate WIV vaccines with greater potency and safety than vaccines produced by current inactivation techniques.

show abstract

“…The methods for pathogen reduction in blood products currently approved in the United States or under study are listed in Table 2 (reviewed in [29]). However, clinicians can also minimize the secondary contamination of blood products by following current requirements that all blood products be transfused within 4 hours of the blood product unit being entered (i.e., spiked) on the clinical unit or returned to the blood bank within 30 minutes if it is not spiked and not to be immediately transfused.…”

Section: Infectionmentioning

confidence: 99%

Transfusion in Critically Ill Children

Parker

2014

Critical Care Medicine

View full text Add to dashboard Cite

The preponderance of prospective, randomized trials and retrospective analyses support the use of a restrictive packed RBC transfusion policy in most clinical conditions in children. Neonatal transfusions guidelines rely largely on "expert opinion" rather than experimental data. Current transfusion practices for both platelets and coagulant products (e.g., fresh-frozen plasma and recombinant-activated factor VII) are poorly aligned with recommended transfusion guidelines. As with adults, current transfusion practices in children often do not reflect implementation of our current knowledge on the need for transfusion. Greater efforts to implement current evidence-based transfusion practices are needed.

show abstract

Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids

Cited by 13 publications

References 25 publications

Characterization of human pegivirus infection in liver transplantation recipients

Characterization of human pegivirus infection in liver transplantation recipients

Chemical-free inactivated whole influenza virus vaccine prepared by ultrashort pulsed laser treatment

Transfusion in Critically Ill Children

Contact Info

Product

Resources

About